Information about medicinal products published on this website is provided for informational purposes only and does not constitute advertising, a public offer, an offer for sale, or instructions for use.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
VACCINE CERVARIX
"Cervarix" is a recombinant vaccine for the prevention of diseases caused by human papillomavirus (HPV) types 16 and 18. It is intended to prevent cervical cancer and other precancerous lesions caused by these types of the virus. Vaccination is recommended for adolescent girls and women aged 9 to 25 to build immunity against oncogenic strains of HPV.
Cervarix is a vaccine against the human papillomavirus (HPV). It protects against two highly oncogenic types of HPV — 16 and 18, which cause about 70% of cervical cancer cases.
🔹 Types of HPV covered
• 16 — the most oncogenic
• 18 — second in significance
There is also cross-protection (not 100%, but significant) against types 31, 33, and 45, which increases the actual protection to about 80–85% of cervical cancer cases.
🔹 What it protects against
• Cervical cancer
• Some precancerous conditions (CIN2/3)
• To a lesser extent — anal canal cancer (indirectly)
Cervarix does not protect against genital warts (as they are caused by types 6 and 11, which are not included in the vaccine).
🔹 Recommended for
• Girls and women aged 9 to 25 years (ideally before the onset of sexual activity).
• It can also be used later (up to 45 years) — at the discretion of a doctor.
🔹 Effectiveness
• Against HPV 16 and 18: ≈95–100% when vaccinated before infection
• Cross-protection: 30–60% against types 31/33/45
• Reduction in cervical cancer risk in countries with mass vaccination: ≈70–80%
🔹 Side effects (usually mild)
• Pain at the injection site
• Fever
• Weakness
• Headache
Serious reactions are extremely rare.
🔹 Types of HPV covered
• 16 — the most oncogenic
• 18 — second in significance
There is also cross-protection (not 100%, but significant) against types 31, 33, and 45, which increases the actual protection to about 80–85% of cervical cancer cases.
🔹 What it protects against
• Cervical cancer
• Some precancerous conditions (CIN2/3)
• To a lesser extent — anal canal cancer (indirectly)
Cervarix does not protect against genital warts (as they are caused by types 6 and 11, which are not included in the vaccine).
🔹 Recommended for
• Girls and women aged 9 to 25 years (ideally before the onset of sexual activity).
• It can also be used later (up to 45 years) — at the discretion of a doctor.
🔹 Effectiveness
• Against HPV 16 and 18: ≈95–100% when vaccinated before infection
• Cross-protection: 30–60% against types 31/33/45
• Reduction in cervical cancer risk in countries with mass vaccination: ≈70–80%
🔹 Side effects (usually mild)
• Pain at the injection site
• Fever
• Weakness
• Headache
Serious reactions are extremely rare.
